StockpollyBeta
Get App
Popularity #1,849
MNKD · NASDAQ · Biotechnology

MannKind (MNKD)

Commercializes Afrezza, FUROSCIX and V-Go while manufacturing Tyvaso DPI for United Therapeutics.

$3.44
After hours−0.04 (−1.15%)
At close$3.48(−0.57%)

  1. MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

    MarketBeat

  2. MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

    GlobeNewsWirePartnership

  3. FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

    Zacks Investment ResearchClinical

  4. MannKind: New Approvals Majorly Increase MannKind's Prospects

    Seeking Alpha

  5. MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

    Seeking Alpha

  6. MannKind Q2 Earnings Call Highlights

    MarketBeat

  7. Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

    Zacks Investment Research

  8. MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

    Zacks Investment Research

  9. MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

    GlobeNewsWire

  10. MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript

    Seeking Alpha

  11. MannKind's Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway

    MarketBeat

  12. MannKind injection helps heart failure patients avoid ER infusions

    Reuters

  13. MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

    GlobeNewsWire

  14. MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

    GlobeNewsWire

  15. MannKind (NASDAQ:MNKD) Shares Gap Up – Still a Buy?

    Defense World

  16. FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

    Benzinga

  17. MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript

    Seeking Alpha

  18. MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE

    MarketBeat

  19. MannKind Announces $50 Million Private Placement

    GlobeNewsWire

  20. MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

    GlobeNewsWire